Mutual of America Capital Management LLC Sells 1,130 Shares of Haemonetics Co. (NYSE:HAE)

Mutual of America Capital Management LLC trimmed its stake in Haemonetics Co. (NYSE:HAE) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,531 shares of the medical instruments supplier’s stock after selling 1,130 shares during the period. Mutual of America Capital Management LLC owned approximately 0.05% of Haemonetics worth $2,072,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 632 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares during the last quarter. KBC Group NV boosted its holdings in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 712 shares in the last quarter. iSAM Funds UK Ltd bought a new position in shares of Haemonetics during the 3rd quarter valued at about $204,000. Finally, Versor Investments LP raised its holdings in shares of Haemonetics by 9.1% during the 3rd quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 300 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Price Performance

HAE stock opened at $68.70 on Friday. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of 27.05, a PEG ratio of 1.11 and a beta of 0.43. The firm’s 50-day moving average price is $69.77 and its two-hundred day moving average price is $75.72. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HAE. Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target for the company. Finally, Barrington Research decreased their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.